Benefits of the Respiratory Panel:

  • Delivers one-day results*
  • Identifies bacteria regardless of recent antibiotic use
  • Identifies difficult to culture pathogens
  • Offers simplicity of single sample collection
  • Yields greater than 95% analytical sensitivity and specificity

* Determined by sample receipt

Respiratory Infection Panel:

    Adenovirus types 3, 4, 7, 21
    Enterovirus group
    Human bocavirus
    Human coronavirus (4 types)
    Human metapneumovirus
    Influenza A - Human influenza
    Influenza A - H1N1-09
    Influenza B
    Parainfluenza virus types 1, 2, 3, 4
    Respiratory Syncytial Virus (A & B)
    Rhinovirus

    Acinetobacter baumannii
    Bordetella pertussis
    Chlamydophila pneumoniae
    Haemophilus influenzae
    Haemophilus influenzae (type B)

    Klebsiella pneumoniae
    Legionella pneumophila
    Moraxella catarrhalis
    Mycoplasma pneumoniae
    Neisseria meningitidis
    Pseudomonas aeruginosa
    Staphylococcus aureus
    MRSA - Meth. resistant S. aureus
    Panton-Valentine leukocidin gene
    Streptococcus pneumoniae
    Streptococcus pyogenes (Group A)

    Staphylococcal Resistance Genes:
    Aminoglycoside
    Cephalosporin
    Erythromycin/Clindamycin
    Methicillin
    Tetracycline

Report Format:

Chief Complaints for Consideration:

  • –  
    Acute bronchiolitis due to infectious organism
  • –  
    Acute bronchitis
  • –  
    Acute nasopharyngitis (common cold)
  • –  
    Acute pharyngitis
  • –  
    Acute sinusitis NOS
  • –  
    Acute tonsillitis
  • –  
    Allergic rhinitis NOS
  • –  
    Asthma NOS
  • –  
    Chronic sinusitis NOS
  • –  
    Cough
  • –  
    Fever NOS
  • –  
    Nasal & sinus disease NEC
  • –  
    Pneumonia, organism NOS
  • –  
    Viral infection NOS
  • –  
    Wheezing

Co-detection data:

* Data on file

Since the 2009 H1N1 epidemic, new light has been shed on the role co-infections may play in the virulence of respiratory infections. Recent studies, such as The impact of bacterial and viral co-infection in severe influenza , suggest that patients who develop more severe respiratory infections often have a co-infection. For more co-detection data and analysis from Diatherix, view this poster presented at IDweek 2013.

Respiratory Panel detection of both bacteria and viruses can improve patient outcomes and reduce healthcare costs.

TEM-PCR™ provides the ability to identify patients with viral, bacterial or both viral and bacterial pathogens from a single specimen in one day and allows the clinician to:

  • •  

    Withhold antibiotics in patients with viral detection

  • •  

    Administer appropriate antibiotic and/or antiviral therapy

  • •  

    Incorporate evidence-based medicine to enhance the quality and cost-effectiveness of patient care